Clinical trial
Mucosal Gene Expression Defects in Patients With Inflammatory Bowel Disease Before and After First Infliximab Therapy
NCT00639821 is registered in ClinicalTrials.gov with KU Leuven as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Mucosal Gene Expression Defects in Patients With Inflammatory Bowel Disease Before and After First Infliximab Therapy
- Lead sponsor
- KU Leuven
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 31, 2004
- Completion date
- February 29, 2008
- Enrollment
- 73 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.